Tag: TAVR

InspireMD’s Cguard Carotid Embolic Prevention System Featured At The SOLACI CACI Congress Of Cardiology 2017 In Buenos Aires

TEL AVIV, ISRAEL–(Marketwired – August 03, 2017) – InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that an endovascular interventional procedure featuring the CGuard™ EPS performed by the team of Dr. Anibal Damonte, Interventional […]

Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval

Press Release DUBLIN – July 10, 2017 – Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic valve replacement (TAVR) platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery. […]

Innovative Cardiovascular Solutions Raises $5.0 Million in Series B Financing for Advanced Device Development and Initiation of U.S. Clinical Activities

KALAMAZOO, Mich., July 11, 2017 /PRNewswire/ — Innovative Cardiovascular Solutions, LLC (ICS), a privately-held clinical stage company headquartered in Kalamazoo, MI, announced today completion of an oversubscribed Series B round of financing totaling $5M USD. The company is currently developing the EMBLOK™ Embolic Protection System which is designed for use in Transcatheter Aortic Valve Replacement […]

Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval

DUBLIN – July 10, 2017 – Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic valve replacement (TAVR) platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery. With hemodynamic […]

Edwards Lifesciences (EW)’ Novel Self-Expanding Transcatheter Heart Valve Demonstrates Excellent Early Patient Outcomes

PARIS, May 17, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced late-breaking data at EuroPCR 2017 demonstrating excellent clinical outcomes for transcatheter aortic valve replacement (TAVR) patients treated with the Edwards CENTERA valve. These new […]

Venus Medtech’s TAVR Device Is Approved By CFDA, Creating A New Era Of Interventional Cardiology In China

HANGZHOU, China, April 28, 2017 /PRNewswire/ — Venus Medtech (Hangzhou) Inc., announced on April 25th that its transcatheter aortic valve system – Venus A-valve – has been approved by China Food and Drug Administration(“CFDA”) (registration no.: 20173460680) for sale in China. This marks the first-ever CFDA approved Transcatheter Aortic Valve Implantation […]

Boston Scientific agrees to acquire Symetis

MARLBOROUGH, Mass., March 30, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices, for $435 million in up-front cash. The Symetis portfolio includes the ACURATE TA™ and ACURATE neo/TF valve* […]

FDA Green Lights Medtronic (MDT)’s CoreValve Evolut Pro Transcatheter Valve With Advanced Sealing

Press Release Medtronic Receives FDA Approval for CoreValve(TM) Evolut(TM) Pro Transcatheter Valve with Advanced Sealing DUBLIN – March 22, 2017 – Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic […]